Linked Life Data

15453120

Source:http://linkedlifedata.com/resource/pubmed/id/15453120

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
34
pubmed:dateCreated
2004-9-29
pubmed:abstractText
The azole antifungal voriconazole and the echinocandin caspofungin have recently become available for the treatment of invasive mycoses. Fluconazole remains the drug of choice for candidemia, except for infections with one of the resistent species such as Candida krusei and some strains of Candida glabrata. In these cases, as well as in patients who cannot tolerate azoles in connection with side effects or drug interactions, caspofungin is an attractive alternative. Voriconazole has become the drug of choice for severe invasive aspergillosis. Itraconazole is a good alternative for milder and chronic forms of aspergillosis. The use of conventional amphotericin B will be limited by the availability of the new drugs. In view of their high costs, the lipid-bound forms of amphotericin B will usually be given only as salvage therapy in case of failure, in patients who are unable to tolerate either conventional amphotericin or one of the newer agents, and for the treatment of zygomycosis.
pubmed:commentsCorrections
pubmed:language
dut
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0028-2162
pubmed:author
pubmed:issnType
Print
pubmed:day
21
pubmed:volume
148
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1679-84
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
[New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin].
pubmed:affiliation
Afd. Infectieziekten, Leids Universitair Medisch Centrum, Leids Centrum voor Infectieziekten, Gebouw 1, C5P, Postbus 9600, 2300 RC Leiden. jwvantwout@planet.nl
pubmed:publicationType
Journal Article, English Abstract, Review